Clinical Trial Update: A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine [Phase 2]

View source ↗

Summary

A Phase 2 human challenge trial update evaluating protection from LimmaTech Biologics' Shigella tetravalent bioconjugate vaccine. The study is currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigellosis

Drugs mentioned

• Shigella tetravalent bioconjugate vaccine (Shigella tetravalent bioconjugate vaccine)

Snippet

Sponsor: LimmaTech Biologics AG | Conditions: Shigellosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING